|
|
| Feb.7 |
Foster City |
Gilead beats Street 4Q forecasts |
|
|
| Sep.13 |
South of Market |
Developer knew about Millennium Tower sinking before selling units |
|
| Feb.2 |
Foster City |
Gilead Sciences beats estimates for 4th-quarter earnings |
|
| Jan.8 |
Santa Clara |
Thermo Fisher adds Affymetrix to biotech toolkit for $1.3B
|
|
| Oct.27 |
Foster City |
Gilead Sciences beats Street 3Q forecasts |
|
| Oct.14 |
Wells Fargo |
Wells Fargo's earnings edge up 1 percent to $5.4 billion
|
| Jul.28 |
Foster City |
Gilead profit beats Wall Street forecasts
|
| Mar.31 |
Brisbane |
Horizon Pharma to buy Brisbane’s Hyperion Therapeutics Horizon Pharma agreed to buy Brisbane’s Hyperion Therapeutics for $1.1 billion to gain drugs to treat rare metabolic diseases
|
| Mar.4 |
Sunnyvale |
Pharmacyclics to sell in biggest biotech deal of the year |
|
|
| Aug.24 |
Brisbane |
Roche buys Brisbane drugmaker InterMune for $8.3 billion| Swiss pharmaceutical giant is expanding its respiratory disease treatments by acquiring InterMune at $74 per share in an all-cash transaction | |
|
| Jul.2 |
Genentech |
Genentech to buy Seragon Pharmaceuticals |
|
| Jun.3 |
San Mateo |
Migraine drug developer acquired for up to $825 million |
|
|
| Sep.2 |
Eastern Span |
New Bay Bridge ready for on-time opening |
|
| Sep.1 |
Eastern Span |
Work moving quickly on new Bay Bridge span| Round-the-clock work to open the new eastern span is proceeding smoothly and transportation officials are putting the finishing touches on a ceremony | |
|
| Aug.27 |
South SF |
Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion to give Amgen access to a rapidly expanding cancer-drug market
|
|
| Nov.16 |
Oakland |
Hostess filing for bankruptcy, closing plants |
|
|
| Nov.21 |
Foster City |
Gilead to buy Pharmasset for $11 billion Gilead Sciences Inc. has agreed to pay about $11 billion for drug developer Pharmasset Inc. in a huge bet on experimental hepatitis C treatments
|
| Jun.1 |
Santa Clara |
Affymetrix names Witney as new CEO |
|
| May.27 |
South SF |
Solazyme's solid IPO Startup that makes algae-based biofuel, raised nearly $200 million; the stock finished on the Nasdaq at $20.71 with a 15% gain
|
| Mar.18 |
Alameda |
Quest to buy Celera for $671 million |
|
|
| Dec.2 |
SF City Hall |
S.F. approves biodiesel plant |
|
| Nov.27 |
Cupertino |
AE Biofuels plans to restart ethanol plant |
|
| Oct.28 |
Menlo Park |
Pacific Biosciences shares jump over IPO 12.5 million shares opened higher than the offering price are pouring another $200 million - in addition to the $375 million it already received in VC
|
| Sep.28 |
Emeryville |
Amyris IPO price holds steady Amyris Biotechnologies, an startup that uses genetically modified yeast to produce biofuel, sold shares for the first time on the Nasdaq, closing at $16
|
| Aug.18 |
Palo Alto |
FDA eyes fibromyalgia drug |
|
| Jul.30 |
Menlo Park |
Geron approved to test stem cells |
|
| Jul.20 |
Genentech |
Panel doesn't back Avastin for cancer |
|
| Jul.2 |
Genentech |
Avastin delays ovarian cancer |
|
| Jun.11 |
Mountain View |
Gene test mix-up draws scrutiny 23andMe acknowledged in a post on its Web site that it mixed up the samples of 96 clients and sent them the wrong ones
|
| May.17 |
San Francisco |
Bayer, Nektar moving into Mission Bay |
|
| Apr.22 |
Redwood City |
Clean-tech IPO brings $78 M to Codexis
|
| Jan.9 |
Genentech |
FDA Approves Actemra Arthritis Drug |
|
|
| Nov.2 |
Oakland |
Clorox Sees 23 Percent Profit Jump |
|
| Oct.27 |
San Francisco |
Medivation to develop cancer drug |
|
| Oct.3 |
San Francisco |
Taker found for Mission Bay office space
|
| Aug.2 |
Genentech |
FDA clears drug for kidney cancer
|
| Jul.9 |
Genentech |
Axe falls at Genentech
|
| Jul.6 |
San Francisco |
Pfizer drops planned research center
|
| Jun.18 |
Google |
Google invests $2.6M in startup
|
| Apr.28 |
Foster City |
Flu's bad news but shot in arm for Gilead |
|
| Apr.22 |
Foster City |
Lawsuit Vs. Gilead To Proceed |
|
| Apr.8 |
Genentech |
Drug Raptiva pulled from market
|
| Mar.26 |
Genentech |
Roche completes purchase of Genentech |
|
| Mar.12 |
Foster City |
Gilead To Buy CV Therapeutics For $1.4 B
|
| |
Genentech |
Roche to take over Genentech for $47B Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
| The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own
|
| |
|
| Mar.9 |
Genentech |
Roche-Genentech deal called close
|
| Mar.6 |
Genentech |
Roche raises bid for Genentech
|
| Mar.3 |
Genentech |
Genentech replies to hostile Roche bid |
|
| Feb.9 |
Genentech |
Roche launches $86.50-a-share bid
|
| Feb.6 |
Genentech |
Roche CEO: Offer for Genentech fair deal |
|
| Feb.3 |
Berkeley |
Elephant Pharm abruptly closes its stores
|
| Jan.30 |
Genentech |
Roche revives takeover bid of Genentech
|
| Jan.28 |
Palo Alto |
Tokyo Drugmaker Eyes CV Therapeutics |
|
| Jan.23 |
Menlo Park |
Geron wins OK for stem cell trial therapy |
|
| Jan.18 |
South SF |
Cell Genesys delisting reprieve extended |
|
|
| Dec.12 |
South SF |
Bristol-Myers joins Exelixis for drugs |
|
| Nov.18 |
Genentech |
Avastin linked to higher risk of clots
|
| Sep.25 |
South SF |
Fluidigm Withdraws IPO |
|
| Sep.19 |
South SF |
Fluidigm pushing forward with IPO |
|
| Aug.27 |
South SF |
Cell Genesys Drug Trial Halts
|
| Aug.21 |
Genentech |
Retention plan to cost $371 million |
|
| Aug.17 |
Genentech |
Recruiters eye Genentech employees |
|
| Aug.13 |
Genentech |
Genentech rejects Roche's $43.7b bid
|
| Aug.6 |
San Francisco |
Pfizer moving biotech research unit to S.F.| The world's largest drugmaker will move the headquarters of its new biotech research unit to Mission Bay, next door to UCSF's new campus | |
|
| Jul.31 |
Genentech |
Shareholders sue to halt Roche buyout |
|
| Jul.25 |
Genentech |
Panel to ponder Roche takeover offer |
|
| Jul.21 |
Genentech |
Roche Offers $44B For Remaining Shares
|
| Jun.12 |
Foster City |
Invitrogen to buy Applied Biosystems Invitrogen agreed to pay $6.4 billion in cash and stock for scientific instruments maker Applera's Applied Biosystems Group
|
| May.20 |
San Jose City Hall |
McKesson Sued On Prices
|
| Apr.30 |
Genentech |
Bad news on cancer drug Rituxan
|
| Apr.24 |
Genentech |
Court slashes $200 million from judgment
|
| Feb.22 |
Genentech |
FDA Clears Avastin for Breast Cancer A Genentech drug received federal approval, a surprise decision
|
| Feb.17 |
South SF |
Prostate cancer vaccine shows promise |
|
| Jan.14 |
Genentech |
4Q Profit Rises 6 Percent |
|
|
| Dec.5 |
Genentech |
FDA Panel Rejects Avastin, stock drops
|
| Nov.20 |
Mountain View |
Startup 23andMe offers DNA scans online |
|
| Oct.16 |
Genentech |
3Q Profit Up 21 % On Cancer Drug Sales |
|
| Oct.12 |
Oakland |
Nurses Not Allowed To Return After Strike |
|
|
| Nov.11 |
Genentech |
Genentech to acquire partner Tanox |
|
| Aug.12 |
Genentech |
Cancer drug review extended |
|
| Jul.31 |
Genentech |
Tony Blair Visits Genentech Headquarters
|
| Jul.11 |
Genentech |
2Q Profit Soars to $531 Million |
|
| Jul.1 |
Genentech |
FDA approves blindness drug |
|
| Apr.12 |
Genentech |
Profit climbs by 48% in first quarter |
|
| Feb.13 |
Genentech |
Cancer Drug Trials Scaled Back
|
| Jan.28 |
San Carlos |
Nektar Develops Inhaled Insulin |
|
| Jan.11 |
Genentech |
Up 64% in quarter after good year |
|
|
| Nov.1 |
Emeryville |
Novartis to buy Chiron| Chiron's board accepted a $5.1 billion purchase offer from Swiss pharmaceutical giant Novartis AG | |
|
| Oct.18 |
Emeryville |
Problems Cause Chiron To Miss Earnings
|
| Oct.13 |
Emeryville |
Chiron gets OK on flu shots |
|
| Jul.11 |
Genentech |
Profits Soar 73% in 2Q |
|
| Jun.15 |
Emeryville |
Chiron Warns on Fewer Flu Vaccines Chiron will not produce as many flu vaccines as previously announced because of production delays
|
| Apr.16 |
Genentech |
Avastin helps those with breast cancer |
|
| Apr.12 |
Genentech |
Biotech giant's profit up 61% |
|
| Mar.5 |
San Francisco |
Sirna Therapeutics moving to Mission Bay |
|
| Mar.2 |
Emeryville |
Regulators Lift Suspension on Chiron British regulators are enabling the company to begin reproducing flu drugs
|
| Jan.26 |
Emeryville |
Chiron's 2004 income falls dramatically Chiron hobbled by its failure to deliver half the nation's flu vaccine last year. It missed analysts' expectations
|
| Jan.10 |
Genentech |
4th best place to work for in U.S. |
|
| |
Genentech |
Profit surges, misses expectations by 1c |
|
|
| Nov.29 |
Genentech |
Avastin helps sickest patients |
|
| Nov.4 |
Brisbane |
VaxGen gets contract for anthrax vaccine The government is purchasing 75 million doses of a new generation vaccine under an $877.5 million
|
| Oct.20 |
Emeryville |
Flu Vaccine Fiasco Costs Chiron Millions |
|
| Oct.15 |
Emeryville |
Board member quits embattled Chiron |
|
| Oct.13 |
Emeryville |
SEC probes Chiron over flu shot shortage |
|
| Oct.6 |
Genentech |
Profits surge on drug sales |
|
| Oct.5 |
Emeryville |
Flu maker Chiron slashes profit outlook Chiron cut its profit forecast by more than half after British officials pulled the company's license
|
| Aug.26 |
San Jose |
Bioscience Incubator welcomes companies |
|
| Aug.16 |
Orinda |
Top Chiron lawyer's home vandalized |
|
| Jun.8 |
SF Downtown |
150 protesters held at biotech conference About 200 demonstrators failed to shut down the annual Biotechnology Industry Organization convention
|
| |
SF Downtown |
Protesters arrested at biotech conference |
|
| Jun.6 |
SF Downtown |
Biotech conference opens 18,000 biotechnology scientists, executives and government officials were welcomed with a mayor and jeering protesters
|
| Apr.7 |
Genentech |
Profits surge on brisk cancer drug sales |
|
| Feb.26 |
Genentech |
FDA approves cancer fighter Avastin |
|
| Jan.14 |
Genentech |
Profits surge on strong drug sales |
|
|
| Dec.16 |
Emeryville |
Chiron sells 375,000 additional flu vaccine |
|
| Nov.5 |
South SF |
Pain Therapeutics: 'abuse-resistant' pill |
|
| Oct.8 |
Genentech |
Biotech titan posts higher profits |
|
| May.19 |
Genentech |
Encouraging results with cancer drug Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45%
|
| Feb.23 |
Brisbane |
AIDS vaccine developed by VaxGen An experimental vaccine does not protect most people, but showed promise in protecting blacks and Asians
|
|
| Sep.7 |
Genentech |
Big patent win vs. Chiron |
World News 
USA 
California 
Bay Area 
Business 
Bio Tech (120)
World Bio Tech
Bio Tech & Bad Economic News (6)
Bio Tech & Science (7)
Bio Tech & Business Lawsuit (13)
Bio Tech & Business Leaders (6)
Bio Tech & Commercial Real Estate (4)
Bio Tech & Earnings (37)
Bio Tech & Good Economic News (10)
Bio Tech & Healthcare Business (4)
Bio Tech & IPO (7)
Bio Tech & Job Cut (4)
Bio Tech & Merger and Acquisition (34)
Bio Tech & Stocks (5)
Bio Tech on Wikipedia
Bio Tech on Web
Chart Time by Topic
World Bio Tech News Timeline 
Good Economic News
Main Event: Horizon Pharm... 
